Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche’s Xeloda  Gets Chinese Approval

This article was originally published in PharmAsia News

Executive Summary

China's State FDA has given its approval to Roche Pharmaceuticals' Xeloda (capecitabine) oral drug for treating gastric cancer. The chemotherapy drug is considered more convenient than injectable versions because it has fewer side effects and avoids a chance of infections. China counts 400,000 people a year diagnosed with gastric cancer and a mortality rate of 300,000 a year, the third most fatal cancer in the country. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts